Quick update on the FDA’s draft policy regarding promotion of off-label drug use, which Gavin blogged about last July. Despite widespread negative…
-
PLoS Medicine FDA’s “Good” Reprint Practices Now Policy
-
In the News Should Patients be Told of Better Care Elsewhere?
This was a question posed by Denise Grady in an article in the New York Times earlier this month. Her piece outlined…
-
In the News Blogging on bias
Publication bias became a big blogging topic last week as a PLoS Medicine paper was picked up by several influential sites. Lisa…
-
PLoS Medicine NEJM opens online discussion on controversial study
Earlier this month the editors of The New England Journal of Medicine invited readers to a more interactive role than we usually…
-
PLoS Medicine Data access and the NHS – more research versus patient privacy?
The Guardian’s front page story from a couple of days ago (“NHS medical research plan threatens patient privacy”) looks like it has…
-
In the News “There’s no easy way to say this. . .”
A Health in Action paper published in PLoS Medicine recently describes the success of an innovative project called inSPOT – an e-card…
-
PLoS Medicine Guest blog by Richard Smith: More evidence on why we need radical reform of science publishing
PLoS Medicine invited Richard Smith, former editor of the BMJ and current board member of PLoS, to discuss an essay published this…
-
In the News Chewing over the Churnalism: PLoS Medicine in NHS Choices
“Few things can make a doctor’s heart sink more in a clinic than a patient brandishing a newspaper clipping”, wrote Ben Goldacre…
-
In the News County by County Life Expectancy: How Many Americas are There?
Over the past couple of weeks Josh Eveleth and I have answered journalists’ enquiries from many different pockets of the United States…
-
In the News Prozac and Placebos: Review of a Media Maelstrom
Last week we had the interesting experience of watching how a PLoS Medicine meta-analysis of anti-depressant drug trials generated a furore in…
-
In the News No Such Thing as a Free Lunch (or Gift or Sample)
Are the staggering amounts spent by drug companies on marketing justified by their innovation in drug development? Not according to a Policy…
-
In the News Fearsome foursome factors of longevity
Following the recent blog that related a PLoS paper to end of year excess, this week a PLoS Medicine study evaluating the…